Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • VistaGen Therapeutics, Inc. (VSTA) Issues Update On $36M Strategic Financing Agreement With Autlion 0 comments
    Jun 28, 2013 3:04 PM | about stocks: VSTA

    VistaGen Therapeutics, a biotech company applying pluripotent stem cell technology for drug rescue, predictive toxicology, and drug metabolism assays, today provided an update on the status of its strategic financing agreement with Autilion AG.

    VistaGen in April signed an initial agreement with Autilion, a Bergamo Acquisition Corp. subsidiary, in which Autilion committed to invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen common stock, at a price of $0.50 per share, in a series of closings ending on or before September 30, 2013.

    Under the terms of the parties' amended agreement, the parties today report that they have completed a first closing and scheduled additional closings to occur in July, August, and September 2013. As previously announced, the self-placed strategic financing does not include warrants or investment banking fees.

    "I met with Autilion's team earlier this week, and we have been working closely with them since signing our agreement in April," Shawn K. Singh, VistaGen's CEO, stated in the press release. "We are confident and excited about completing this transformative financing. Building on the positive developments in our labs presented during the Annual Meetings of the Society of Toxicology and International Society of Stem Cell Research in March and this month, respectively, we look forward to accelerating our lead programs towards valuable outcomes for our shareholders."

    VistaGen's drug rescue activities integrate the company's human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to create novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates.

    For more information, visit www.vistagen.com

    Please see disclaimer on the MissionIR website
    http://www.missionir.com/disclaimer.html

    Stocks: VSTA
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.